Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R²) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018

Pivotal phase 3 data show investigational R 2 significantly extended progression-free survival compared with rituximab plus placebo. Positive trend in overall survival was observed. Regulatory submissions planned for Q1 2019.